Study suggest CAR T-Cell therapy effective as first line treatment for high risk large B-cell lymphoma

Share This Post

March 2022: The University of Texas MD Anderson Cancer Center researchers discovered that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR T-cell therapy), is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group in desperate need of new and effective treatments.

These findings were presented at the American Society of Hematology’s virtual 2020 Annual Meeting.

Traditionally, around half of patients with high-risk LBCL, a subgroup of the disease in which patients have double- or triple-hit lymphoma or additional clinical risk factors identified by the International Prognostic Index (IPI), have not achieved long-term disease remission with standard treatment approaches such as chemoimmunotherapy.

“This trial represents a step toward making CAR T cell therapy a first-line treatment option for patients with aggressive B-cell lymphoma,” said Sattva S. Neelapu, M.D., professor of Lymphoma and Myeloma. “At the moment, patients with newly diagnosed aggressive B-cell lymphoma get chemotherapy for about six months. CAR T cell therapy, if successful, may make it a one-time infusion with treatment completed in one month.”

Based on the key research ZUMA-1, Axi-cel is presently licenced for the treatment of people with relapsed or refractory LBCL who have already had two or more lines of systemic treatments. The ZUMA-12 trial is a Phase 2 open-label, single-arm, multicenter trial that builds on the findings of the ZUMA-1 trial to assess the use of axi-cel as first-line therapy for patients with high-risk LBCL.

According to the ZUMA-12 interim study, 85 percent of patients treated with axi-cel had an overall response, and 74% had a complete response. After a median follow-up of 9.3 months, 70% of the patients recruited exhibited a continuing response at the data cutoff.

White blood cell count reduction, encephalopathy, anaemia, and cytokine release syndrome were the most common side effects linked with axi-cel treatment. By the time the data was analysed, all adverse events had been resolved.

Furthermore, when compared to when the immunotherapy products were generated from patients who had already received several lines of chemotherapy, the peak level of CAR T cells present in the blood, as well as the median CAR T cell expansion, were higher in this trial of first-line CAR T cell therapy.

“This T cell fitness could be linked to greater therapeutic effectiveness, resulting in better patient outcomes,” Neelapu added.

Following the excellent interim results of ZUMA-12, the researchers plan to continue following up with the patients to ensure that their reactions to the medication are long-lasting.

“A randomised clinical trial would be required to definitely demonstrate that CAR T cell therapy is superior to existing standard of care with chemoimmunotherapy in these high-risk patients if the responses are persistent after prolonged follow-up,” Neelapu said. “It also begs the question of whether CAR T cell treatment should be tested in intermediate-risk patients with big B-cell lymphoma.”

Apply for CAR T-Cell therapy

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Polatuzumab
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form

https://cancerfax.com/